Payment overview · 2025
General Payments
$493.61
14 reported records · 4 companies
Healthcare provider profile · identity verified
Guido Gonzalez
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · HIALEAH, FL · NPI 1922578392
Verified facts
What the public records show
CMS Open Payments records show Guido Gonzalez received $493.61 in general payments during 2025 across 14 reported records.
Otsuka America Pharmaceutical, Inc. accounted for 71.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Linzess.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 104 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Lumigan by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 110 claims for Farxiga by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $352.28 | 71.4% | 9 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $87.31 | 17.7% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $30.53 | 6.2% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $23.49 | 4.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $493.61 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $439.59 | 12 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $30.53 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $23.49 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 110 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 104 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
104 | 20 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
110 | 20 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 395 | 60 |
| Quetiapine Fumarate | Quetiapine Fumarate | 273 | 43 |
| Amlodipine Besylate | Amlodipine Besylate | 263 | 42 |
| Pantoprazole Sodium | Pantoprazole Sodium | 249 | 38 |
| Tamsulosin Hcl | Tamsulosin Hcl | 225 | 35 |
| Metformin Hcl | Metformin Hcl | 202 | 28 |
| Lisinopril | Lisinopril | 189 | 27 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 173 | 35 |
| Ketoconazole | Ketoconazole | 171 | 24 |
| Losartan Potassium | Losartan Potassium | 169 | 26 |
| Gabapentin | Gabapentin | 168 | 33 |
| Omeprazole | Omeprazole | 141 | 24 |
| Levothyroxine Sodium | Levothyroxine Sodium | 140 | 24 |
| Memantine Hcl | Memantine Hcl | 136 | 24 |
| Clopidogrel | Clopidogrel Bisulfate | 135 | 22 |
| Hydrochlorothiazide | Hydrochlorothiazide | 127 | 20 |
| Carvedilol | Carvedilol | 123 | 21 |
| Famotidine | Famotidine | 120 | 17 |
| Eliquis | Apixaban | 119 | 26 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 116 | 23 |
| Ammonium Lactate | Ammonium Lactate | 112 | 24 |
| Furosemide | Furosemide | 111 | 25 |
| Farxiga | Dapagliflozin Propanediol | 110 | 20 |
| Lactulose | Lactulose | 110 | 21 |
| Diclofenac Sodium | Diclofenac Sodium | 106 | 20 |
| Linzess | Linaclotide | 104 | 20 |
| Trazodone Hcl | Trazodone Hcl | 99 | 31 |
| Metoprolol Succinate | Metoprolol Succinate | 97 | 19 |
| Metoprolol Tartrate | Metoprolol Tartrate | 94 | 14 |
| Mirtazapine | Mirtazapine | 90 | 20 |
| Montelukast Sodium | Montelukast Sodium | 88 | 16 |
| Ssd | Silver Sulfadiazine | 85 | 22 |
| Memantine Hcl Er | Memantine Hcl | 81 | 13 |
| Fenofibrate | Fenofibrate Nanocrystallized | 80 | 13 |
| Donepezil Hcl | Donepezil Hcl | 77 | 15 |
| Mupirocin | Mupirocin | 74 | 26 |
| Escitalopram Oxalate | Escitalopram Oxalate | 72 | 12 |
| Megestrol Acetate | Megestrol Acetate | 70 | 17 |
| Sertraline Hcl | Sertraline Hcl | 70 | 18 |
| Entresto | Sacubitril/Valsartan | 64 | 15 |
| Azithromycin | Azithromycin | 63 | 51 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 63 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 62 | 16 |
| Alprazolam | Alprazolam | 61 | suppressed |
| Glipizide | Glipizide | 60 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 60 | suppressed |
| Hydrocortisone | Hydrocortisone | 59 | 16 |
| Divalproex Sodium | Divalproex Sodium | 58 | suppressed |
| Atenolol | Atenolol | 57 | suppressed |
| Ibuprofen | Ibuprofen | 57 | suppressed |
| Finasteride | Finasteride | 53 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 53 | 15 |
| Potassium Chloride | Potassium Chloride | 52 | suppressed |
| Levetiracetam | Levetiracetam | 48 | suppressed |
| Xarelto | Rivaroxaban | 48 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 47 | 13 |
| Simvastatin | Simvastatin | 47 | suppressed |
| Latanoprost | Latanoprost | 46 | suppressed |
| Temazepam | Temazepam | 43 | 12 |
| Lorazepam | Lorazepam | 42 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 41 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 40 | suppressed |
| Valsartan | Valsartan | 40 | suppressed |
| Clonazepam | Clonazepam | 39 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 39 | suppressed |
| Timolol Maleate | Timolol Maleate | 39 | suppressed |
| Pentoxifylline | Pentoxifylline | 38 | suppressed |
| Allopurinol | Allopurinol | 37 | suppressed |
| Nifedipine Er | Nifedipine | 36 | suppressed |
| Spironolactone | Spironolactone | 36 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 33 | suppressed |
| Digoxin | Digoxin | 33 | suppressed |
| Glimepiride | Glimepiride | 33 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 32 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 32 | suppressed |
| Cephalexin | Cephalexin | 31 | 28 |
| Vascepa | Icosapent Ethyl | 30 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 29 | suppressed |
| Levofloxacin | Levofloxacin | 29 | 29 |
| Risperidone | Risperidone | 29 | suppressed |
| Bumetanide | Bumetanide | 28 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 28 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 27 | suppressed |
| Irbesartan | Irbesartan | 25 | suppressed |
| Carbamazepine | Carbamazepine | 24 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 24 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 24 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 23 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 22 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 22 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 22 | suppressed |
| Aripiprazole | Aripiprazole | 21 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 21 | suppressed |
| Ciclopirox | Ciclopirox | 20 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 20 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 20 | suppressed |
| Meloxicam | Meloxicam | 20 | suppressed |
| Nystatin | Nystatin | 20 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 20 | suppressed |
| Jardiance | Empagliflozin | 19 | suppressed |
| Sucralfate | Sucralfate | 19 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 18 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 18 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 17 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 17 | suppressed |
| Januvia | Sitagliptin Phosphate | 17 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 17 | suppressed |
| Baclofen | Baclofen | 16 | suppressed |
| Cilostazol | Cilostazol | 16 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 16 | suppressed |
| Lubiprostone | Lubiprostone | 16 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 15 | suppressed |
| Fenofibrate | Fenofibrate | 15 | suppressed |
| Fluocinolone Acetonide Oil | Fluocinolone Acetonide Oil | 15 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Myrbetriq | Mirabegron | 15 | suppressed |
| Lumigan | Bimatoprost | 14 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 14 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 14 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 13 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 13 | suppressed |
| Enulose | Lactulose | 13 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 13 | suppressed |
| Amantadine | Amantadine Hcl | 12 | suppressed |
| Brilinta | Ticagrelor | 12 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Haloperidol | Haloperidol | 12 | suppressed |
| Klor-Con M20 | Potassium Chloride | 12 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | 11 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 12 | suppressed |
| Repaglinide | Repaglinide | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | 12 |
| Zenpep | Lipase/Protease/Amylase | 12 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Diclofenac Sodium Er | Diclofenac Sodium | 11 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 11 | suppressed |
| Travoprost | Travoprost | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $493.61 · 14 records | Otsuka America Pharmaceutical, Inc. | FARXIGA, LINZESS, REXULTI | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error